(thirdQuint)ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma.

 OBJECTIVES: I.

 Determine the complete and partial response rates and duration of response in patients with locally advanced, unresectable, or metastatic non-small cell lung cancer or unresectable or metastatic melanoma treated with ISIS 3521.

 II.

 Determine safety of ISIS 3521 in these patients.

 OUTLINE: This is a multicenter study.

 Patients are stratified by disease type.

 Patients receive ISIS 3521 IV over 21 days followed by 7 days of rest.

 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A total of 28-50 patients (14-25 per stratum) will be accrued for this study.

.

 ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of ISIS 3521 in treating patients who have advanced, unresectable, or metastatic non-small cell lung cancer or unresectable or metastatic melanoma.

